Thomas Ebel
Papers
1
Total Citations
40
H-Index
1
About
Dr. Thomas Ebel is a leading figure in the translational genomics of ovarian cancer, with a sharp focus on homologous recombination deficiency (HRD) as a critical biomarker for targeted therapy. In his landmark 2022 study, “Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort,” Dr. Ebel demonstrated the diagnostic power of next-generation sequencing to evaluate HRD across 514 ovarian carcinoma samples. By analyzing DNA libraries that included BRCA1/BRCA2 and over 26,000 single-nucleotide polymorphisms, his work provided a robust, real-world framework for identifying patients most likely to benefit from PARP inhibitors. This highly cited contribution (40 citations) has helped bridge the gap between genomic discovery and routine clinical decision-making, directly influencing how oncologists stratify treatment. Dr. Ebel’s research not only advances precision oncology but also underscores the importance of integrating comprehensive genomic profiling into standard care, making him a pivotal voice in the fight against ovarian cancer.
Research Focus
Key Achievements
Top Papers
- 1